Download PDF
Dtsch Med Wochenschr 2021; 146(22): 1457-1467
DOI: 10.1055/a-1391-5124
Dossier

Die neoadjuvante und adjuvante Therapie des resektablen Kolonkarzinoms: Aktuelle Standards und Entwicklungen

Neoadjuvant and adjuvant therapy of resectable colon cancerCurrent standards and developments
Volker Heinemann
,
Sebastian Stintzing
› Further Information
Also available at
    Permissions and Reprints

Die vorliegende Übersichtsarbeit konzentriert sich auf die perioperative Diagnose und Behandlung des resezierbaren Kolonkarzinoms. In UICC-Stadien, die mit einem höheren Rezidivrisiko verbunden sind, ist die adjuvante Chemotherapie nach Resektion des Primärtumors ein etablierter Standard. Erste Daten weisen zwar auch auf den Nutzen einer neoadjuvanten, präoperativen Chemotherapie hin, eine endgültige Bewertung steht jedoch noch aus.

Abstract

The present review focusses on perioperative diagnosis and treatment of resectable colon cancer. In UICC stages associated with a higher risk of recurrence, adjuvant chemotherapy after resection of the primary tumor is an established standard. While initial data also indicate the benefit of Neoadjuvant, pre-operative chemotherapy, a final evaluation is still pending. The main focus of molecular testing in the perioperative setting is the analysis of microsatellite instability, which should routinely be performed in defined subgroups. In UICC stage II without risk factors, adjuvant therapy has a limited benefit and therefore is not a preferred option. In UICC stage II with risk factors, adjuvant therapy can be performed. The approach here is based on the recommendations applicable to stage III. In UICC stage III with low risk, adjuvant chemotherapy with CAPOX for 3 months is preferentially recommended. In UICC stage III with high risk, adjuvant chemotherapy over 6 months is recommended, preferentially with FOLFOX. Microsatellite instability (MSI) is clearly associated with favorable prognosis in non-metastatic colon cancer. However, it cannot be considered a predictive factor for the efficacy of adjuvant chemotherapy. Specifically, recent data of the IDEA study have opened the arena for shared decision making between physicians and patients allowing to define individual treatment approaches based on common assessment of risks and benefits. After completion of perioperative treatment, structured follow-up is of great importance and should be carried out according to the recommendations of the S3 guideline.

Schlüsselwörter

Kolonkarzinom - molekulare Subgruppen - adjuvante Therapie - neoadjuvante Therapie - gemeinsame Entscheidungsfindung

Key words

colon cancer - molecular subgroups - adjuvant therapy - neoadjuvant therapy - shared decision making


Publication History

Article published online:
05 November 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Roth AD, Tejpar S, Delorenzi M. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28: 466-474
    CrossrefPubMedGoogle Scholar
  • 2 Benson AB, Venook AP, Al-Hawary MM. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19: 329-359
    CrossrefPubMedGoogle Scholar
  • 3 AWMF online. Leitlinienprogramm Onkologie. S3-Leitlinie Kolorektales Karzinom 2019, Langversion 2.1. Januar 2019. AWMF-Registernummer: 021/007OL
    PubMedGoogle Scholar
  • 4 Sargent DJ, Goldberg RM, Jacobson SD. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097
    CrossrefPubMedGoogle Scholar
  • 5 Fata F, Mirza A, Craig G. et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 2002; 94: 1931-1938
    CrossrefPubMedGoogle Scholar
  • 6 Hoshino N, Aoyama R, Hida K. Survival benefit of adjuvant chemotherapy in elderly patients with colon cancer: a systematic review and meta-analysis. Int J Clin Oncol 2021; ahead of print
    PubMedGoogle Scholar
  • 7 Rosati G, Lonardi S, Galli F. et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial. Eur J Cancer 2021; 148: 190-201
    CrossrefPubMedGoogle Scholar
  • 8 Bradley CJ, Given CW, Dahman B. et al. Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. Arch Intern Med 2008; 168: 521-529
    CrossrefPubMedGoogle Scholar
  • 9 Neugut AI, Matasar M, Wang X. et al. Duration of adju- vant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375
    CrossrefPubMedGoogle Scholar
  • 10 Yothers G, O'Connell MJ, Allegra CJ. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774
    CrossrefPubMedGoogle Scholar
  • 11 Tournigand C, Andre T, Bonnetain F. et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-3360
    CrossrefPubMedGoogle Scholar
  • 12 McCleary NJ, Meyerhardt JA, Green E. et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600-2606
    CrossrefPubMedGoogle Scholar
  • 13 Haller DG, O'Connell MJ, Cartwright TH. et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 2015; 26: 715-724
    CrossrefPubMedGoogle Scholar
  • 14 Biagi JJ, Raphael MJ, Mackillop WJ. et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011; 305: 2335-2342
    CrossrefPubMedGoogle Scholar
  • 15 Meulendijks D, Henricks LM, Sonke GS. et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 1639-1650
    CrossrefPubMedGoogle Scholar
  • 16 Quasar Collaborative Group et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
    CrossrefPubMedGoogle Scholar
  • 17 Andre T, De Gramont A, Vernerey D. et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 2015; 33: 4176-4187
    CrossrefPubMedGoogle Scholar
  • 18 Benson 3rd AB, Schrag D, Somerfield MR. et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419
    CrossrefPubMedGoogle Scholar
  • 19 Pahlman LA, Hohenberger WM, Matzel K. et al. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated?. J Clin Oncol 2016; 34: 1297-1299
    CrossrefPubMedGoogle Scholar
  • 20 Verhoeff SR, van Erning FN, Lemmens VE. et al. Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer 2016; 139: 187-193
    CrossrefPubMedGoogle Scholar
  • 21 Dalerba P, Sahoo D, Paik S. et al. CDX2 as a prognostic biomarker in stage II and stage III colon cancer. N Engl J Med 2016; 374: 211-222
    CrossrefPubMedGoogle Scholar
  • 22 Tie J, Wang Y, Tomasetti C. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8: 346 ra 392
    PubMedGoogle Scholar
  • 23 Iveson TJ, Sobrero AF, Yoshino T. et al. Duration of adjuvant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol 2021; 39: 631-641
    CrossrefPubMedGoogle Scholar
  • 24 André T, Boni C, Mounedji-Boudiaf L. et al. Multicenter International Study of Oxaliplatin/5- Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
    CrossrefPubMedGoogle Scholar
  • 25 Schmoll HJ, Tabernero J, Maroun J. et al. Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 2015; 33: 3733-3740
    CrossrefPubMedGoogle Scholar
  • 26 Grothey A, Sobrero AF, Shields AF. et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 2018; 378: 1177-1188
    CrossrefPubMedGoogle Scholar
  • 27 Andre T, Vernerey D, Mineur L. et al. Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open- Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. J Clin Oncol 2018; 36: 1469-1477
    CrossrefPubMedGoogle Scholar
  • 28 Sobrero A, Lonardi S, Rosati G. et al. FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial. J Clin Oncol 2018; 36: 1478-1485
    CrossrefPubMedGoogle Scholar
  • 29 Iveson TJ, Kerr RS, Saunders MP. et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol 2018; 19: 562-578
    CrossrefPubMedGoogle Scholar
  • 30 Sargent D, Sobrero A, Grothey A. et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009; 27: 872-877
    CrossrefPubMedGoogle Scholar
  • 31 Salem ME, Yin J, Goldberg RM. et al. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann Oncol 2020; 31: 480-486
    CrossrefPubMedGoogle Scholar
  • 32 Sobrero AF, Puccini A, Shi Q. et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur J Cancer 2020; 138: 182-188
    CrossrefPubMedGoogle Scholar
  • 33 Sinicrope FA, Mahoney MR, Smyrk TC. et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III co- lon cancer from a randomized trial of FOLF- OX-based adjuvant chemotherapy. J Clin Oncol 2013; 31: 3664-3672
    CrossrefPubMedGoogle Scholar
  • 34 Yoon HH, Tougeron D, Shi Q. et al. Alliance for Clinical Trials in Oncology. KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 2014; 20: 3033-3043
    CrossrefPubMedGoogle Scholar
  • 35 Taieb J, Le Malicot K, Shi Q. et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J Natl Cancer Inst 2016; 109: djw272
    CrossrefPubMedGoogle Scholar
  • 36 Sargent DJ, Marsoni S, Monges G. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226
    CrossrefPubMedGoogle Scholar
  • 37 Bertagnolli MM, Redston M, Compton CC. et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803. J Clin Oncol 2011; 29: 3153-3162
    CrossrefPubMedGoogle Scholar
  • 38 Schiappacasse Cocio GV, Schiappacasse ED. Is Adjuvant Chemotherapy Efficient in Colon Cancer with High Microsatellite Instability? A Look Towards the Future. Cancer Res 2019; 79: 441-444
    CrossrefPubMedGoogle Scholar
  • 39 Seymour MT, Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer [abstract]. J Clin Oncol 2019; 37: 3504
    CrossrefPubMedGoogle Scholar
  • 40 Chalabi M, Fanchi LF, Dijkstra KK. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med 2020; 26: 566-576
    CrossrefPubMedGoogle Scholar